Markets:

Overview

News

Currencies

International

Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.605 -0.055 (-2.07%)

Streaming Delayed Price Updated: 11:44 AM EDT, Aug 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗

December 05, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Nkarta Stock (NKTX) Is Volatile During Monday's Session? ↗

December 05, 2022

Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 05, 2022

The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today!

Via InvestorPlace

SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside ↗

July 18, 2022

Via Benzinga

Expert Ratings for Nkarta ↗

April 26, 2022

Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter:

Via Benzinga

Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses ↗

April 25, 2022

Via Benzinga

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

December 05, 2022

From Nkarta, Inc.

Via GlobeNewswire

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

November 09, 2022

From Nkarta, Inc.

Via GlobeNewswire

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

November 07, 2022

From Nkarta, Inc.

Via GlobeNewswire

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers ↗

October 25, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via Benzinga

7 Unknown Biotech Stocks That Could Rocket in 2023 ↗

September 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Via InvestorPlace

Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes ↗

August 12, 2022

Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading.

Via Benzinga

Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments? ↗

June 14, 2022

Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗

July 28, 2022

Via Benzinga

Positive Clinical Results Put Nkarta Stock on the Fast Track ↗

May 09, 2022

NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program.

Via InvestorPlace

Executives Buy More Than $32M Of 3 Stocks ↗

May 02, 2022

Although US stocks closed sharply lower on Friday, there were a few notable insider trades.

Via Benzinga

How Is The Market Feeling About Nkarta Inc. - Common Stock? ↗

April 27, 2022

Nkarta Inc. - Common Stock's (NASDAQ:NKTX) short percent of float has risen 8.05% since its last report. The company recently reported that it has 1.84 million shares sold short,...

Via Benzinga

71 Biggest Movers From Yesterday ↗

April 27, 2022

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

April 26, 2022

Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday...

Via Benzinga

Futures Slide Ahead Of Tech Earnings Deluge ↗

April 26, 2022

Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices.

Via Talk Markets

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 26, 2022

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

April 26, 2022

HC Wainwright & Co. raised Nkarta, Inc. (NASDAQ: NKTX) price target from $25 to $36. Nkarta shares fell 7.2% to $17.38 in pre-market trading.

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares Slide ↗

April 25, 2022

U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 points on Monday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 25, 2022

Via Benzinga

60 Biggest Movers From Yesterday ↗

April 26, 2022

Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two...

Via Benzinga

Mid-Day Market Update: Crude Oil Tumbles Over 6%; Nkarta Shares Spike Higher ↗

April 25, 2022

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 400 points on Monday.

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

April 25, 2022

Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose finding studies of its two lead chimeric antigen...

Via Benzinga

Why Is Nkarta (NKTX) Stock Soaring 90% Today? ↗

April 25, 2022

Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Nkarta, Inc. - Common Stock (NQ:NKTX)

All News about Nkarta, Inc. - Common Stock

Resources